Selected article for: "clinical management and convalescent plasma"

Author: Galluccio, Felice; Ergonenc, Tolga; Garcia Martos, Alvaro; Allam, Abdallah El-Sayed; Pérez-Herrero, Maria; Aguilar, Ricardo; Emmi, Giacomo; Spinicci, Michele; Terrancle Juan, Ignacio; Fajardo-Pérez, Mario
Title: Treatment algorithm for COVID-19: a multidisciplinary point of view
  • Cord-id: ik5rdhlo
  • Document date: 2020_5_29
  • ID: ik5rdhlo
    Snippet: The novel coronavirus (Sars-CoV-2) pandemic has spread rapidly, from December to the end of March, to 185 countries, and there have been over 3,000,000 cases identified and over 200,000 deaths. For a proportion of hospitalized patients, death can occur within a few days, mainly for adult respiratory distress syndrome or multi-organ dysfunction syndrome. In these patients, clinical signs and symptoms, as well as laboratory abnormalities, suggest a cytokine storm syndrome in response to the viral
    Document: The novel coronavirus (Sars-CoV-2) pandemic has spread rapidly, from December to the end of March, to 185 countries, and there have been over 3,000,000 cases identified and over 200,000 deaths. For a proportion of hospitalized patients, death can occur within a few days, mainly for adult respiratory distress syndrome or multi-organ dysfunction syndrome. In these patients, clinical signs and symptoms, as well as laboratory abnormalities, suggest a cytokine storm syndrome in response to the viral infection. No current targeted treatment is yet available for COVID-19, an unknown disease up to 2 months ago, which challenges doctors and researchers to find new drugs or reallocate other treatments for these patients. Since the beginning of the COVID-19 outbreak, a growing body of information on diagnostic and therapeutic strategies has emerged, mainly based on preliminary experience on retrospective studies or small case series. Antivirals, antimalarials, corticosteroids, biotechnological and small molecules, convalescent plasma and anticoagulants are among the drugs proposed for the treatment or in tested for COVID-19. Given the complexity of this new condition, a multidisciplinary management seems to be the best approach. Sharing and integrating knowledge between specialists, to evaluate the correct timing and setting of every treatment, could greatly benefit our patients. We reviewed the literature, combining it with our experiences and our specialist knowledge, to propose a management algorithm, correlating the clinical features with laboratory and imaging findings to establish the right timing for each treatment.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory infectious disease and low peripheral: 1
    • acute respiratory infectious disease and lung density: 1
    • acute respiratory infectious disease and lung involvement: 1, 2
    • acute respiratory infectious disease and lung periphery: 1
    • acute respiratory infectious disease and lung ultrasound: 1, 2
    • acute viral respiratory infection and lopinavir ritonavir: 1
    • acute viral respiratory infection and lung density: 1
    • additional study and lopinavir ritonavir: 1, 2
    • additional study and lung involvement: 1
    • lopinavir ritonavir and lpv rtv initiation: 1, 2
    • lopinavir ritonavir and lpv rtv lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • lopinavir ritonavir and lpv rtv lopinavir ritonavir antiviral treatment: 1
    • lopinavir ritonavir and lung density: 1, 2
    • lopinavir ritonavir and lung involvement: 1, 2, 3, 4, 5
    • lopinavir ritonavir and lung ultrasound: 1
    • low peripheral and lung involvement: 1